Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes

Micheva, Ilina; Thanopoulou, Eleni; Michalopoulou, Sotiria; Καρακάντζα, Μαρίνα; Kouraklis-Symeonidis, Alexandra; Mouzaki, Αthanasia; Zoumbos, Nicholas

doi:10.1016/j.clim.2004.08.007

Cited by 28 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, it has been shown that monocyte-derived dendritic cells (MoDCs) from MDS patients are numerically and functionally defective (1, 52). DCs are considered one of the most potent antigen presenting cells (APC), They usually differentiate from circulating monocytes under “danger” mediators' effect such as lipopolysaccharadies, TNF-α or other cytokines.…”

Section: Discussionmentioning

confidence: 99%

“…The autoimmunity is believed to be triggered by the increased apoptosis in the dysplastic bone marrow. Recent evidence suggests that both diseases are characterized by dendritic (1) and T-cell (2) abnormalities. AD presentation varies from clinical syndromes such as vasculitis, lupus and rheumatoid arthritis to laboratory abnormalities such as thrombocytopenia, hemolytic anemia and autoantibodies (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature

et al. 2013

View full text Add to dashboard Cite

Our objective was to recognize the association of autoimmune disease (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature

et al. 2013

View full text Add to dashboard Cite

show abstract

“…However, immature monocyte-derived dendritic cells (MoDCs) from MDS patients produced less IL-12 and substantially more IL-10 in response to lipopolysaccharide (LPS)/IFN-c as compared to normal MoDCs (Ma et al, 2007a). Similarly, Micheva et al (2004) demonstrated impaired ability of immature MoDCs from MDS patients to become mature DCs upon stimulation with TNF-a, although the allostimulatory capacity upon LPS stimulation was comparable to healthy control-derived MoDC. These maturation defects should be taken into account when considering autologous MoDC vaccination in high-risk MDS and alternative maturation cocktails may be necessary.…”

Section: Immune Activating Strategies For the Treatment Of High-risk Mdsmentioning

confidence: 99%

Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy

et al. 2011

View full text Add to dashboard Cite

SummaryThe myelodysplastic syndromes (MDS) constitute a group of heterogeneous clonal haemopoietic stem cell disorders, characterized by ineffective and dysplastic haematopoiesis with varying degrees of peripheral cytopenia. Low-risk MDS is characterized by increased apoptosis in the bone marrow (BM) with autoimmune characteristics whereas the advanced or high-risk stages involve immune evasion and secondary DNA damage, giving cells growth potential to progress into acute myeloid leukaemia (AML). Nevertheless, the causes of MDS remain poorly defined and it is not clear how the disease progresses from an early stage to advanced MDS and AML. Although there are clear indications for a role of the immune system, the exact mechanism by which the immune response contributes to the progression is not yet clear. New insights into the pathophysiology of MDS with regard to the immune system will be instrumental for the development of novel patient-oriented therapies. This review is focused on the role of immune responses in MDS and the implications for the development of novel immune therapies.

show abstract

“…A number of immunoregulatory abnormalities have been described. Studies have shown that patients with MDS have reduced numbers of helper T cells [8], abnormal monocyte-derived dendritic cells [9], dysfunctional T regulatory cells [10], increased interferon regulatory factor-1 (IRF-1), m-RNA expression [11], decreased natural killer (NK) cell activity, and abnormalities of antibody-dependent cell killing [12]. …”

Section: Discussionmentioning

confidence: 99%

Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome

Merrill

Smith

2011

Case Reports in Hematology

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) commonly presents asymptomatically or with symptomatic cytopenias. However, autoimmune phenomena in association with MDS have been well described in several case reports and case series. Typically, these autoimmune phenomena take the form of vasculitides, arthritis, connective tissue diseases, pulmonary infiltrates, or polymyalgia rheumatica. We present the case of a woman with MDS (karyotype 46,XX,+1,der(1;7)(q10;p10)[20], that evolved with an additional trisomy 8 clone) and a novel spectrum of autoimmune diseases including acute fibrinous and organizing pneumonia (AFOP) and lacrimal gland pseudotumor.

show abstract

Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes

Cited by 28 publications

References 27 publications

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature

Myelodysplastic syndromes and autoimmune diseases—Case series and review of literature

Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy

Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome

Contact Info

Product

Resources

About